Drug Trial Radar · NCT05806359
A Study to Evaluate the Safety, Tolerability, and Drug Levels of Danicamtiv in Healthy Japanese and Caucasian Participants
Last checked: Nov 20, 2026Latest source record: May 23, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
33
Actual
Start
Mar 31, 2023
Primary completion
Aug 14, 2023
Study completion Aug 14, 2023
Sponsor
- Lead sponsor
- Bristol-Myers SquibbBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- Apr 10, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the safety, tolerability, and single-dose pharmacokinetics of danicamtiv in healthy Japanese and Caucasian participants.
Conditions
- Healthy Volunteers
Interventions
DanicamtivDrug
Specified dose on specified days
PlaceboDrug
Specified dose on specified days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with Adverse Events (AEs)Time frame: Day 1 up to Day 28
- Number of Participants with Vital Sign AbnormalitiesTime frame: Day 1 up to Day 7
- Number of Participants with Electrocardiogram (ECG) AbnormalitiesTime frame: Day 1 up to Day 7
- Number of Participants with Physical Examination AbnormalitiesTime frame: Day 1 up to Day 7
- Number of Participants with Clinical Laboratory AbnormalitiesTime frame: Day 1 up to Day 7
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Anaheim Clinical Trials
Anaheim, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.